Disc Medicine, Inc. (IRON): Total Liabilities
$67.05M
As of 2025-12-31
$90.91M
As of 2026-06-30
+41.6%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $67.05M | +26.1% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $53.19M | +132.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $22.88M | -3.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $23.61M | +59.9% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $14.76M | n/c | 2023-03-31, Balance as of period end |
| 2020-12-31 | $30.18M | n/a | 2022-03-10, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | 2025-12-31 | $67.05M | +26.1% |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | $153.75M | +7.8% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $509.73M | +128.3% |
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
| uniQure N.V. (QURE) | 2025-12-31 | $626.01M | +11.1% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $420.83M | n/m |
| Belite Bio, Inc (BLTE) | 2025-12-31 | $10.07M | +59.6% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $188.85M | +17.3% |
| Spyre Therapeutics, Inc. (SYRE) | 2025-12-31 | $62.55M | -31.0% |
Compare IRON, OCUL, VREOF, MNKD side by side · Screen every company in Pharmaceutical Preparations ↗